Tuesday, 16 April 2013

Non -Hodgkin Lymphoma - Pipeline Review, H1 2013 New Research Report Available at Industry Monitor

Global Markets Directs, 'Non -Hodgkin Lymphoma Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Non -Hodgkin Lymphoma, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non -Hodgkin Lymphoma. Non -Hodgkin Lymphoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

To Buy the Copy Of This Report Visit: http://www.industrymonitor.co/report/165659-non

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • A snapshot of the global therapeutic scenario for Non -Hodgkin Lymphoma.
  • A review of the Non -Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry -specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Non -Hodgkin Lymphoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
For Request The Sample of this Report Visit: http://www.industrymonitor.co/sample/sample/165659

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Non -Hodgkin Lymphoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter -strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Non -Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in -licensing and out -licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contact US

Hemendra Pratap
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030


Post a Comment

Note: only a member of this blog may post a comment.


Twitter Delicious Facebook Digg Stumbleupon Favorites More